GLOBAL BLOOD THERAPEUTICS, INC.

(GBT)
  Report
Delayed Nasdaq  -  04:00 2022-08-09 pm EDT
66.59 USD   -0.02%
08/09Global Blood Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Raised to $68.50 From $60 Amid Pfizer Deal
MT
08/09SVB Securities Downgrades Global Blood Therapeutics to Market Perform from Outperform, Sets $68.50 Price Target
MT
08/09Wells Fargo Downgrades Global Blood Therapeutics to Equalweight From Overweight, Adjusts Price Target to $68.50 From $66
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer in advanced talks to buy Global Blood Therapeutics for $5 billion - WSJ

08/05/2022 | 11:44am EDT
FILE PHOTO: People pose with syringe with needle in front of displayed Pfizer logo

(Reuters) - Pfizer Inc is in advanced talks to buy drugmaker Global Blood Therapeutics for about $5 billion, the Wall Street Journal reported on Friday, citing people familiar with the matter.

(Reporting by Amruta Khandekar; Editing by Aditya Soni)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
GLOBAL BLOOD THERAPEUTICS, INC. -0.02% 66.59 Delayed Quote.127.50%
PFIZER, INC. 0.42% 49.78 Delayed Quote.-16.05%
All news about GLOBAL BLOOD THERAPEUTICS, INC.
08/09Global Blood Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Ta..
MT
08/09SVB Securities Downgrades Global Blood Therapeutics to Market Perform from Outperform, ..
MT
08/09Wells Fargo Downgrades Global Blood Therapeutics to Equalweight From Overweight, Adjust..
MT
08/09Cantor Fitzgerald Downgrades Global Blood Therapeutics to Neutral From Overweight, Adju..
MT
08/09William Blair Downgrades Global Blood Therapeutics to Market Perform From Outperform
MT
08/09Cowen Downgrades Global Blood Therapeutics to Market Perform From Outperform, Adjusts P..
MT
08/09NORTH AMERICAN MORNING BRIEFING : Stocks to -2-
DJ
08/09GLOBAL BLOOD : Q2 Earnings Snapshot
AQ
08/09BioPharma Credit To Receive Loan Prepayment Following Pfizer's Takeover Of Global Blood..
MT
08/09Pfizer scoops up Global Blood Therapeutics in $5.4bn deal
AQ
More news
Analyst Recommendations on GLOBAL BLOOD THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 282 M - -
Net income 2022 -306 M - -
Net cash 2022 173 M - -
P/E ratio 2022 -14,1x
Yield 2022 -
Capitalization 4 492 M 4 492 M -
EV / Sales 2022 15,3x
EV / Sales 2023 10,1x
Nbr of Employees 457
Free-Float 88,1%
Chart GLOBAL BLOOD THERAPEUTICS, INC.
Duration : Period :
Global Blood Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLOBAL BLOOD THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Last Close Price 66,59 $
Average target price 67,89 $
Spread / Average Target 1,96%
EPS Revisions
Managers and Directors
Ted W. Love President, Chief Executive Officer & Director
Jeffrey S. Farrow Chief Financial & Accounting Officer
Mark L. Perry Chairman
Kim Smith-Whitley Executive VP, Head-Research & Development
Kenneth R. Bridges Medical Director & Vice President-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
GLOBAL BLOOD THERAPEUTICS, INC.127.50%4 492
MODERNA, INC.-32.62%71 566
LONZA GROUP AG-26.08%43 806
IQVIA HOLDINGS INC.-17.18%43 579
SEAGEN INC.13.58%32 890
ALNYLAM PHARMACEUTICALS, INC.31.72%27 695